29Jul
National Retailer Pulls CBD Products From Shelves in Response to FDA Warning to Product Manufacturer
On Monday, July 22, the U.S. Food and Drug Administration (FDA) took a rare and significant step in issuing a warning letter to Curaleaf Holdings, Inc. (Curaleaf), one of the country’s larger producers of CBD-based products, regarding Curaleaf’s...
By:
Manatt, Phelps & Phillips, LLP
Related
The United States Supreme Court unanimously decided last week that a plan participant who received w...
Read More >
Many employers use background checks to guarantee it hires the best candidates—and to minimize lega...
Read More >
Antitrust regulators in the United States and Europe were very active in the final quarter of 2019. ...
Read More >
Below are summaries of recent laws adopted in Washington State that could be interpreted as relating...
Read More >
Under the new Massachusetts Paid Family and Medical Leave Law, M.G.L c. 175M (“MAPFML”), employees...
Read More >
This edition of Employment Flash looks at recent NLRB activity, including its issuance of a decision...
Read More >